Why It Matters
The Pentagon has elevated biomanufacturing to its second-highest research priority, driven by supply chain vulnerabilities and strategic competition with China over synthetic biology capabilities. Congress responded with 17 new biotechnology provisions in the FY 2026 NDAA, authorizing a new Pentagon Biotechnology Management Office, commercialization programs, and supply chain resiliency initiatives.
BioMADE’s lobbying targets the appropriations mechanisms that will determine how billions flow to this DoD-sponsored institute. The legislative landscape is fluid and receptive, with bills like the Biotechnology Supply Chain Resiliency Act (H.R.5186) and the Biomanufacturing Excellence Act (H.R.6089) directly aligned with BioMADE’s mission. But competition is fierce: Genomatica Inc. and Synonym Biotechnologies are also lobbying to shape defense dollar distribution.
By the Numbers
BioMADE spent $70,000 inthe last quarteron federal lobbying, continuing an exclusive four-year relationship with Holland & Knight LLP. The organization has filed 16 consecutive quarterly disclosures since May 2022, totaling $1.17 million in cumulative spending on identical issues: bioindustrial manufacturing and Department of Defense budget advocacy.
Holland & Knight deploys a six-person lobbying team led by Daniel J. Sennott, former Minority Staff Director for the House Armed Services Committee, whose congressional experience provides direct access to defense budgeting decisions. Kathleen L. Nicholas has represented BioMADE on all 16 filings since inception.
The Agenda
BioMADE is lobbying on two interconnected issues: bioindustrial manufacturing and the FY26 Department of Defense budget. The Defense Department-sponsored Manufacturing Innovation Institute has maintained unwavering focus across every quarterly disclosure.
The timing aligns with substantial congressional momentum. Multiple bipartisan bills now pending—including the Biotechnology Supply Chain Resiliency Act (H.R.5186), the Biomanufacturing Excellence Act (H.R.6089), and the National Biotechnology Initiative Act (H.R.2756)—directly address BioMADE’s core mission of building domestic bioindustrial capacity.
Broader Context
Congress is rapidly elevating bioindustrial manufacturing from a niche issue to a centerpiece of national security strategy. The FY 2026 National Defense Authorization Act includes 17 biotechnology provisions and ranks biomanufacturing as the Pentagon’s second-highest research priority. This shift reflects deep concern about China’s dominance in biotech.
Key bipartisan legislation moving through the 119th Congress includes the H.R.5186 – Biotechnology Supply Chain Resiliency Act, which would authorize DoD to assess vulnerabilities and fund collaborative research on bioindustrial production, and the H.R.6089/S.3188 – Biomanufacturing Excellence Act, backed by Senators Chris Coons (D-DE) and Ted Budd (R-NC) to establish a National Biopharmaceutical Manufacturing Center of Excellence.
Between The Lines
The recently signed FY 2026 NDAA authorized the Department of Defense to establish a Biotechnology Management Office, launch a bioindustrial manufacturing commercialization program, and create supply chain resiliency accelerators. Bipartisan momentum is evident, with the House BIOTech Caucus co-chaired by Rep. Chrissy Houlahan (D-PA) driving policy priorities in defense authorization debates.
Competitive Landscape
BioMADE faces a crowded but aligned competitive landscape. Genomatica Inc. has spent $200,000 in 2025 lobbying on biobased manufacturing in the NDAA and Farm Bill. Synonym Biotechnologies is lobbying on the Distributed Bioindustrial Manufacturing Program and defense innovation initiatives.
This reflects broader congressional appetite for domestic biomanufacturing investment. Multiple stakeholders appear united in advocating for expanded federal investment, with disagreement likely focused on funding allocation rather than fundamental policy direction.
The Bottom Line
BioMADE’s sustained three-year investment in Holland & Knight—totaling $1.17 million—positions it to influence implementation of new Pentagon authorities, though the ultimate allocation of appropriations remains in flux. Congressional momentum is genuine, with bipartisan legislation directly aligned with BioMADE’s mission moving through the 119th Congress. However, competitive lobbying pressure from other biotech firms pursuing similar funding means BioMADE must navigate a crowded policy landscape to capture outsized influence over the rapidly expanding biomanufacturing industrial base.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article